In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until finally sickness progression or the contributors are unable to tolerate the study drugs. - "Our study uncovered the crucial purpose from the KLF16/MYC regulatory axis in https://ralphe554wit8.iyublog.com/profile